

## CORRIGENDUM

**Corrigendum to: Functional *KRAS* mutations and a potential role for PI3K/AKT activation in Wilms tumors**

The following disclosure has been added to the original article (Polosukhina *et al.*, 2017). Dr. Arteaga was on a Novartis Advisory Board at the time of publication, but the Board service was unrelated to this study.

**Reference**

Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R *et al.* (2017) Functional *KRAS* mutations and a potential role for PI3K/AKT activation in Wilms tumors. *Mol Oncol* **11**, 405–421. <https://doi.org/10.1002/1878-0261.12044>